SAB Biotherapeutics (SABS) PT Lowered to $12 at Chardan Capital Markets
Tweet Send to a Friend
Chardan Capital Markets analyst Keay Nakae lowered the price target on SAB Biotherapeutics (NASDAQ: SABS) to $12.00 (from $20.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
